Vir Biotechnology (VIR) Non-Current Assets (2018 - 2026)

Vir Biotechnology has disclosed Non-Current Assets across 9 years of filings, most recently posting $502.6 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $502.6 million, up 33.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 16.7% YoY), and the FY2025 annual result was $488.7 million, up 37.15% from the prior year.
• Non-Current Assets came in at $502.6 million for Q1 2026 at Vir Biotechnology, up from $488.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $580.9 million in Q1 2024 to a low of $275.7 million in Q3 2023.
• The 5-year median for Non-Current Assets is $356.4 million (2024), against an average of $386.9 million.
• Across the five-year window, Non-Current Assets soared 124.31% in 2022 and sank 35.35% in 2025, its largest moves.
• Vir Biotechnology's Non-Current Assets stood at $283.0 million in 2022, then increased by 16.9% to $330.8 million in 2023, then climbed by 7.71% to $356.4 million in 2024, then soared by 37.15% to $488.7 million in 2025, then increased by 2.84% to $502.6 million in 2026.
• The last three Non-Current Assets figures came in at $502.6 million (Q1 2026), $488.7 million (Q4 2025), and $473.8 million (Q3 2025), per Business Quant data.